This initiative aims to simplify EU legislation on medical devices and diagnostics to enhance competitiveness, foster innovation and ensure proportionate, cost-effective safety requirements while maintaining high levels of patient protection and public health.
This initiative seeks to revise EU CO₂ emission standards for new cars and vans to support a fact-based, economically viable and socially fair transition toward zero-emission mobility.
The Commission presents a proposal to enhance the control of drug precursors, the chemical substances that are used by both legitimate industries and in the production of illicit drugs. As Europe’s drug market evolves, the proposal strengthens authorities to respond to emerging drugs and production processes.
The Multimodal digital mobility services (MDMS) initiative is aimed to support the development of multimodal ticketing services within and across passenger transport modes, with the intention to significantly improve multimodality, inclusiveness and sustainability in the EU, within Member States and across borders.
The Single Digital Booking and Ticketing Regulation (SDBTR) aims to make rail travel more accessible by allowing passengers to book multi-operator journeys through a single digital platform. It focuses specifically on expanding digital access to rail tickets and fares and reduces ticketing fragmentation while ensuring passengers retain their rights throughout the entire journey.
The exploratory opinion examines how to balance the economic benefits of tourism with the protection of local communities by regulating short-term rentals, mitigating over-tourism, strengthening connectivity, and promoting sustainable, inclusive tourism across Europe.
This exploratory opinion on the request of the Cyprus Council presidency is focused on the implementation of the Startups and Scaleup Strategy, with particular emphasis on the forthcoming European Innovation Act (EIA), planned for 2026. The EU Startup and Scaleup Strategy seeks to make Europe the leading hub for launching and expanding global technology-driven companies, including deep tech ventures.
The upcoming Cyprus Presidency of the Council of the EU has asked the EESC to draw up an exploratory opinion aimed at providing insight and recommendation on the establishment of the European centre of clinical excellence for pharmaceuticals, with the view to serve as a unified, evidence-based authority issuing pharmacotherapy recommendations, guidelines, and protocols for a wide range of diseases.
The next Consumer Agenda 2025-2030, scheduled for adoption on 19 November 2025, will include a new action plan on consumers in the single market ensuring a balanced approach that protects consumers without overburdening companies with red tape.
The opinion assesses the revision of the General Block Exemption Regulation to evaluate its practical functioning and propose ways to simplify, broaden and clarify the EU State aid framework.
